Overcoming drug resistance in glioblastoma: new options in sight?

References

[1] Tan AC,López GY,Friedman HS.Management of glioblastoma: State of the art and future directions..CA Cancer J Clin2020;70:299-312

[2] Egaña L,Andermatten J.Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital..Sci Rep2020;10:18445 PMCID:PMC7595088

[3] Yekula A,Beecroft A.The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas..Cancer Drug Resist2020;3:[Online First]

[4] Oliver L,Salaud C,Cartron PF.Drug resistance in glioblastoma: are persisters the key to therapy?.Cancer Drug Resist2020;3:287-301

[5] Riganti C,Caldera V.Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway..Neuro Oncol2013;15:1502-17 PMCID:PMC3813413

[6] Towner RA,Saunders D.Novel approaches to combat chemoresistance against glioblastomas..Cancer Drug Resist2020;3:686-98

[7] Richardson TE,Xing C,Walker JM.Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma..J Neuropathol Exp Neurol2020;79:1031-37

[8] Jovčevska I.Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma..Front Oncol2020;10:798 PMCID:PMC7243123

[9] DeCordova S,Tsolaki AG.Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma..Front Immunol2020;11:1402 PMCID:PMC7379131

[10] Daniel P,Chaddad A.Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities..Front Oncol2019;9:41 PMCID:PMC6369148

[11] Schiffer D,Caldera V.Garami M.The Brain Adjacent to Tumor (BAT)..Management of CNS Tumors.2011;InTech Open197-224

[12] Banelli B,Forlani A.Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells..Oncotarget2017;8:34896-910 PMCID:PMC5471020

[13] Rabé M,Álvarez-Arenas A.Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma..Cell Death Dis2020;11:19 PMCID:PMC6944699

[14] Anderson G.Glioblastoma chemoresistance: roles of the mitochondrial melatonergic pathway..Cancer Drug Resist2020;3:334-55

[15] Salaroglio IC,Kopecka J.Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma..Oncotarget2015;6:1128-42 PMCID:PMC4359222

[16] Martínez-González A,Lloret M.Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma..Cancer Drug Resist2020;3:623-35

[17] Lazzarato L,Blangetti M.Combination of PDT and NOPDT with a Tailored BODIPY Derivative..Antioxidants (Basel)2019;8:531 PMCID:PMC6912809

[18] Chegaev K,Gazzano E.Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance..ACS Med Chem Lett2017;8:361-5 PMCID:PMC5346994

[19] Girotti AW,Korytowski W.Nitric oxide-elicited resistance to anti-glioblastoma photodynamic therapy..Cancer Drug Resist2020;3:401-14 PMCID:PMC7558220